AbbVie Inc. (ABBV) Short-Term Debt
The short-term debt for AbbVie Inc. (ABBV) is $8.75 Billion with a year-over-year change of +28.59%. Short-term debt includes all borrowings and debt obligations due within one year, including the current portion of long-term debt, commercial paper, and credit facilities.
ABBV Short-Term Debt Chart
Current Short-Term Debt
$8.75B
$8.75 Billion
Year-over-Year Change
+28.59%
vs. $6.80B prior year
Historical Data
16
Years of data available
Annual Short-Term Debt History
| Year | Short-Term Debt | YoY Change | % Change |
|---|---|---|---|
| 2025 | $8.75B | +$1.95B | +28.59% |
| 2024 | $6.80B | $-387.00M | -5.38% |
| 2023 | $7.19B | +$2.89B | +67.15% |
| 2022 | $4.30B | $-8.37B | -66.05% |
| 2021 | $12.67B | +$4.00B | +46.05% |
| 2020 | $8.68B | +$4.92B | +131.20% |
| 2019 | $3.75B | $-1.55B | -29.30% |
| 2018 | $5.31B | $-1.11B | -17.26% |
| 2017 | $6.42B | +$6.01B | +1495.77% |
| 2016 | $402.00M | $-2.03B | -83.46% |
| 2015 | $2.43B | $-2.01B | -45.24% |
| 2014 | $4.44B | +$4.01B | +929.93% |
| 2013 | $431.00M | $-611.00M | -58.64% |
| 2012 | $1.04B | +$1.03B | +6412.50% |
| 2011 | $16.00M | +$16.00M | — |
| 2010 | $0 | — | — |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael